Benzinga·2025-10-21 12:16Core Insights - U.S. stock futures showed slight gains, with Dow futures up approximately 0.1% [1] Company Performance - PACCAR Inc reported a significant decline in shares, falling 18.3% to $7.64 in pre-market trading after disappointing third-quarter results [1] - The company's quarterly earnings were $1.12 per share, missing the analyst consensus estimate of $1.17 per share [1] - PACCAR's quarterly sales were reported at $6.107 billion, also below the analyst consensus estimate of $6.371 billion [1] Other Stocks Movement - Neuphoria Therapeutics Inc shares plummeted 65.3% to $5.35 after its AFFIRM-1 trial for social anxiety failed to meet endpoints [4] - Citius Pharmaceuticals Inc shares fell 18.2% to $1.48 following a $6 million registered direct offering announcement [4] - Galapagos NV shares declined 15.4% to $28.99 as the company plans to wind down its Cell Therapy Business [4] - Silvercorp Metals Inc shares decreased by 9.9% to $6.35 in pre-market trading [4] - Other notable declines included Theravance Biopharma Inc down 8.6% to $13.07 and Pacira Biosciences Inc down 8.3% to $21.10 [4]